Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00425321 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 259
- Enrollment target
NCT00425321: Completed Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
NCT00425321 is a Phase 2 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 259 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00425321, a Phase 2 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 259 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the safety and tolerability of 100, 200, and 300 mg/day doses of RWJ-445380 for up to 12 weeks in patients with active Rheumatoid Arthritis despite methotrexate therapy.
Interventions
- DRUG Placebo
- DRUG RWJ-445380 100 mg
- DRUG RWJ-445380 200 mg
- DRUG RWJ-445380 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 259 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
What the finished NCT00425321 record still lists
NCT00425321 is an interventional study that assigns participants to a tested intervention. The registered 259 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00425321 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00425321 about?
NCT00425321 is a clinical study titled "Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy". The primary objective of the study is to evaluate the safety and tolerability of 100, 200, and 300 mg/day doses of RWJ-445380 for up to 12 weeks in patients with active Rheumatoid Arthritis despite methotrexate therapy.
What is the current status of trial NCT00425321?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 259 participants. The study started on 2006-12. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00425321?
The interventions under investigation include: Placebo (DRUG), RWJ-445380 100 mg (DRUG), RWJ-445380 200 mg (DRUG), RWJ-445380 300 mg (DRUG).
Who is sponsoring clinical trial NCT00425321?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00425321's enrollment target sits among peer trials
259 212th of 2000 higher than 1,789 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02361320 · 259 participants · NA
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
- NCT06797258 · 259 participants · NA
FlexHD® Pliable Investigation in Implant-Based Breast Reconstruction
- NCT06990425 · 259 participants · NA
CLOSM Trial: Groin Closure Using Layered Option for Suture Material
- NCT07399977 · 259 participants · NA
Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia